What is ONI?
Headquartered in Oxford, United Kingdom, ONI specializes in the development and commercialization of super-resolution microscopes. The company's proprietary technology enables researchers to visualize biological processes at the nanoscale, providing unprecedented clarity that traditional optical systems cannot achieve. By bridging the gap between complex engineering and practical laboratory application, ONI serves a diverse clientele ranging from academic research institutions to pharmaceutical enterprises. Their market position is defined by a commitment to democratizing high-end imaging, allowing for more efficient drug discovery and a deeper understanding of cellular mechanisms, which remains a core driver of their enterprise-level growth strategy.
How much funding has ONI raised?
ONI has raised a total of $76.7M across 2 funding rounds:
Angel/Seed
$1.7M
Series B
$75M
Angel/Seed (2016): $1.7M with participation from Oxford Sciences Enterprises and Oxford Technology Management
Series B (2022): $75M led by Section 32, Vertical Venture Partners, Artis Ventures Management Iii, Casdin Capital, and ARCH Venture Partners
Key Investors in ONI
Section 32
A venture capital firm founded by Bill Maris that focuses on investing in cutting-edge technology and supporting visionary entrepreneurs at the forefront of technological advancement.
Vertical Venture Partners
An early-stage venture capital firm that specializes in enterprise technology companies, leveraging deep industry expertise to drive growth and operational efficiency.
Artis Ventures Management Iii
A dedicated venture capital fund focused on Tech Bio and Health, investing in data-driven life sciences companies that utilize AI and engineering to enhance human health.
What's next for ONI?
With the recent influx of capital, ONI is well-positioned to accelerate its commercial expansion and R&D initiatives. The company is expected to focus on scaling its manufacturing capabilities to meet the rising global demand for high-resolution imaging solutions. Furthermore, the strategic alignment with its investor base suggests a continued emphasis on integrating AI-driven analytics into their microscopy platforms, potentially unlocking new revenue streams in personalized medicine and therapeutic development. As ONI transitions from a high-growth startup to an established enterprise player, the focus will likely shift toward deepening its footprint in international markets and expanding its portfolio of diagnostic tools.
See full ONI company page
